XML 51 R39.htm IDEA: XBRL DOCUMENT
v3.21.4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Changes in the balances of intangible assets (Details) - USD ($) $ in Thousands | 12 Months Ended
--- | ---
Sep. 30, 2021 | Sep. 30, 2020
Finite-lived Intangible Assets |  |
Amortization of intangible assets beginning balance | $ 4,261 | $ 2,883
Amortization | (1,768) | (703)
Amortization of intangible assets ending balance | 24,233 | 4,261
Pre-Clinical Research Services, Inc. |  |
Finite-lived Intangible Assets |  |
Acquisition |  | 2,081
HistoTox Labs |  |
Finite-lived Intangible Assets |  |
Acquisition | 8,500 |
Bolder BioPATH |  |
Finite-lived Intangible Assets |  |
Acquisition | 12,500 |
BioReliance Corporation |  |
Finite-lived Intangible Assets |  |
Acquisition | 640 |
Gateway Pharmacology Laboratories LLC |  |
Finite-lived Intangible Assets |  |
Acquisition | 100 |
Trademarks |  |
Finite-lived Intangible Assets |  |
Amortization of intangible assets beginning balance | 1,429 | 1,072
Amortization | (109) | (103)
Amortization of intangible assets ending balance | 1,320 | 1,429
Trademarks | Pre-Clinical Research Services, Inc. |  |
Finite-lived Intangible Assets |  |
Acquisition |  | 460
Client Relationships |  |
Finite-lived Intangible Assets |  |
Amortization of intangible assets beginning balance | 2,570 | 1,670
Amortization | (1,413) | (380)
Amortization of intangible assets ending balance | 21,197 | 2,570
Client Relationships | Pre-Clinical Research Services, Inc. |  |
Finite-lived Intangible Assets |  |
Acquisition |  | 1,280
Client Relationships | HistoTox Labs |  |
Finite-lived Intangible Assets |  |
Acquisition | 6,800 |
Client Relationships | Bolder BioPATH |  |
Finite-lived Intangible Assets |  |
Acquisition | 12,500 |
Client Relationships | BioReliance Corporation |  |
Finite-lived Intangible Assets |  |
Acquisition | 640 |
Client Relationships | Gateway Pharmacology Laboratories LLC |  |
Finite-lived Intangible Assets |  |
Acquisition | 100 |
Non-Compete Agreements |  |
Finite-lived Intangible Assets |  |
Amortization of intangible assets beginning balance | 258 | 131
Amortization | (244) | (93)
Amortization of intangible assets ending balance | 1,714 | 258
Non-Compete Agreements | Pre-Clinical Research Services, Inc. |  |
Finite-lived Intangible Assets |  |
Acquisition |  | 220
Non-Compete Agreements | HistoTox Labs |  |
Finite-lived Intangible Assets |  |
Acquisition | 1,700 |
Backlog |  |
Finite-lived Intangible Assets |  |
Amortization |  | (121)
Backlog | Pre-Clinical Research Services, Inc. |  |
Finite-lived Intangible Assets |  |
Acquisition |  | 121
Patents |  |
Finite-lived Intangible Assets |  |
Amortization of intangible assets beginning balance | 4 | 10
Amortization | (2) | (6)
Amortization of intangible assets ending balance | 2 | 4
Patents | Pre-Clinical Research Services, Inc. |  |
Finite-lived Intangible Assets |  |
Acquisition |  | $ 0
Patents | HistoTox Labs |  |
Finite-lived Intangible Assets |  |
Acquisition | 0 |
Patents | Bolder BioPATH |  |
Finite-lived Intangible Assets |  |
Acquisition | 0 |
Patents | BioReliance Corporation |  |
Finite-lived Intangible Assets |  |
Acquisition | 0 |
Patents | Gateway Pharmacology Laboratories LLC |  |
Finite-lived Intangible Assets |  |
Acquisition | $ 0 |

X
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274 + Details
Name: | us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 926 -SubTopic 20 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsRollForward
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275 + Details
Name: | us-gaap_FinitelivedIntangibleAssetsAcquired1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=notv_PreClinicalResearchServicesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=notv_HistotoxLabsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=notv_BolderBioPTHMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=notv_BioRelianceCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=notv_GatewayPharmacologyLaboratoriesLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=notv_ClientRelationshipsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OrderOrProductionBacklogMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |